Major Depressive Disorder Clinical Trial
— MOODOfficial title:
Mobile Observation Of Depression
NCT number | NCT05815459 |
Other study ID # | MOOD |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 15, 2022 |
Est. completion date | February 1, 2023 |
Verified date | May 2023 |
Source | Emteq Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary aim of this project is to test if OCOsense glasses can function as a digital phenotyping tool derived from behavioural and physiological signals related to facial expression and motion recorded using the glasses.
Status | Completed |
Enrollment | 84 |
Est. completion date | February 1, 2023 |
Est. primary completion date | February 1, 2023 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: All participants: - Ability to read & understand English. This is because the majority of our questionnaires are validated in the English language only. - Able to walk, sit, lay and stand unaided Clinical cases: ? = 15 on the Patient health Questionnaire-9 (PhQ9) (moderate to severe depression) Exclusion Criteria: Healthy control participants: - Self-reported current or past history (suspected or diagnosed) of any psychiatric condition - <5 on the Generalised Anxiety Disorder-7 questionnaire (GAD-7) - <5 on the PhQ-9 (no depression) - Receiving medication for any psychiatric disorder (excluding fibromyalgia) All participants: - < 18 years of age or >40 years of age - Anatomical constraints that affect fit (e.g. facial disfigurement) - Facial nerve damage which limits the ability to make facial expressions - Body Mass Index (BMI) >29.9 which we deem may affect physical mobility |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Emteq Labs | Brighton | East Sussex |
Lead Sponsor | Collaborator |
---|---|
Emteq Ltd |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The demonstration of a significant association between facial expression-derived objective valence and self-reported subjective mood under controlled exposure | Measures of facial muscular activation in the corrugator supercilli and zygomaticus major muscles. By comparing the ratio of corrugator to zygomatic muscle activation, the OCOsense glasses will produce:
- Objective valence at a given time (ratio/intensity of corrugator to zygomatic muscle activation at that time). |
4 hours | |
Primary | The demonstration of a significant association between facial expression derived objective mood and self-reported subjective mood under controlled exposure | Measures of facial muscular activation in the corrugator supercilli and zygomaticus major muscles. By measuring corrugator and zygomatic muscle activation, the OCOsense glasses will produce:
- Objective mood during negatively valenced exposures, neutrally valenced exposures and positively valenced exposures described in terms of expression intensity and variability for each exposure. |
4 hours | |
Primary | Identifying physical activity engagement. | The OCOsense glasses contain Inertial Measurement Units (IMU) sensors. By detecting inertial displacement over time OCOsense will detect:
- Movement: a measure of movement over a period of time - specifically, how much of the time period is spent (i) stationary, (ii) in motion, (iii) fidgeting, (iv) engaging with a variety of activities of daily living |
2 hours | |
Secondary | Investigating the relationship between vocal prosody and self-reported subjective mood | The OCOsense glasses contain a microphone. By detecting vocal parameters over time OCOsense will detect:
- the nonsemantic lexical features of speech related to pitch and tone whilst participants verbally recall a positive event in their life or engage with a semi-structured diagnostic interview. |
2 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |